Lilly's gastric cancer drug meets late-stage goal
Oct 15 (Reuters) - Eli Lilly and Co said a late-stage study of its experimental gastric cancer drug met its main goal of improving overall survival.
The study, compared the drug ramucirumab to a placebo and the drug was tested as a second-line treatment in patients with cancers that originate in the stomach.
The study, named REGARD, also improved survival without the cancer worsening.
- Children's corpses in Korean ferry reveal desperate attempts to escape |
- Obama reassures Japan, other allies on China ahead of visit |
- Ukraine government resumes offensive, hopes for more U.S. help |
- Ukraine president calls for new anti-rebel offensive as crisis deal falters |
- Search for MH370 reveals a military vulnerability for China